NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Miromatrix Medical Inc. (NASDAQ: MIRO) to United Therapeutics Corporation is fair to Miromatrix shareholders. Under the terms of the proposed transaction, United Therapeutics would acquire all outstanding shares of Miromatrix for $3.25 per share in cash and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix’s kidney product known as mirokidney™ by December 31, 2025.
Halper Sadeh encourages Miromatrix shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.
The investigation concerns whether Miromatrix and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Miromatrix shareholders; (2) determine whether United Therapeutics is underpaying for Miromatrix; and (3) disclose all material information necessary for Miromatrix shareholders to adequately assess and value the merger consideration. On behalf of Miromatrix shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh encourages Miromatrix shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
